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Abstract
Fracture stabilization in the diabetic patient is associated with higher complication rates,
particularly infection and impaired wound healing, which can lead to major tissue damage,
osteomyelitis, and higher amputation rates. With an increasing prevalence of diabetes and an aging
population, the risks of infection of internal fixation devices are expected to grow. Although
numerous retrospective clinical studies have identified a relationship between diabetes and
infection, currently there are few animal models that have been used to investigate postoperative
surgical site infections associated with internal fixator implantation and diabetes. We therefore
refined the protocol for inducing hyperglycemia and compared the bacterial burden in controls to
pharmacologically induced type-1 diabetic rats after undergoing internal fracture plate fixation and
Staphylococcus aureus surgical site inoculation. Using an initial series of streptozotocin doses,
followed by optional additional doses to reach a target blood glucose range of 300–600 mg/dl, we
reliably induced diabetes in 100% of the rats (n=16) who maintained a narrow hyperglycemic
range 14 days after onset of diabetes (466 ± 16 mg/dl, mean ± SEM; coefficient of variation =
0.15). With respect to our primary endpoint, we quantified a significantly higher infectious burden
in inoculated diabetic animals (median 3.2 × 1010 CFU/mg dry tissue) when compared to
inoculated non-diabetics (7.2 × 104 CFU/mg dry tissue). These data support our hypothesis that
uncontrolled diabetes adversely affects the immune system’s ability to clear S. aureus associated
with internal hardware.
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Diabetes mellitus affects 26 million individuals in the United States1, causing a growing
incidence of non-healing ulcers with limb and digit amputations. Diabetic patients are at
increased risk of bone fractures, often requiring internal hardware2–4.
Over two million orthopedic procedures are performed annually involving implantable
materials5. Indwelling devices are associated with a variety of complications, most
importantly infection causing soft tissue damage and osteomyelitis4,8,9. These infections are
generally difficult to manage and necessitate prolonged antibiotic therapy and revision
surgery5–7. The overall infection rate for implanted hardware is about 5% with 40% of these
infections caused by Staphylococcus aureus8.
Diabetic patients undergoing orthopedic surgery have increased rates of peri-operative
complications9,10. Several large-scale case series studied predictability of post-operative
infection11–15, with infection rates in diabetic patients of 7–10% compared to 1% in non-
diabetics. Currently, there are few experimental models to study post-operative surgical site
infections in diabetic animals after hardware implantation, limiting quantitative evaluation
of new therapies. Therefore, we investigated an experimental model for type-1 diabetes in
rats that allows quantification of the bacterial burden after hardware implantation and
inoculation with S. aureus.
2. Materials and Methods
Fixation plates
Stainless steel fracture plates (2.0 mm, Synthes, Paoli, IL) were cut into 1cm segments. Self-
tapping stainless steel cortical screws were cut to a length of 4–5mm.
Bacterial Husbandry
A methicillin-sensitive strain of S. aureus derived from a previously resistant strain of
Colindale (termed COL, thought to be strain 9204) was provided by Dr. Vance Fowler,
Section of Infectious Diseases, Duke University. Stationary phase cultures of S. aureus were
grown from −80°C stock overnight at 37°C in an 8ml TSB tube. Aliquots of 100μl were
transferred into a fresh 8ml TSB tubes and incubated at 37°C for 5hr to obtain a log phase
culture. This yielded 2 × 108 CFU/ml as estimated by comparison to the 1.0 McFarland
standard. Serial dilution and culture plating were used to confirm reproducibility.
In Vivo Studies
This protocol was approved by the Duke University Animal Care and Use Committee. Male
CD Rats (150–200g) were obtained from Charles River Laboratories (Raleigh, NC). Rats
were given streptozotocin (STZ; VWR, Radnor, PA) injections of 40 mg/kg in citrate buffer
consecutively for 3 days, with a fasting period of 8 hours on Day 1 prior to injection3,7. Rats
were given water supplemented with 15 g/l sucrose for 48h to protect from STZ-induced
insulin release. Forty-eight hours after the third injection, 3-hour fasting blood glucose
measurements were taken via tail vein using a standard glucometer (One Touch Ultra,
LifeScan, Milpitas, CA).
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Rats with a fasting blood glucose level on Day 5 of <350 mg/dl received a fourth dose of
STZ. This procedure was repeated every other day until the target blood glucose was
achieved. Rats in the non-diabetic group received three vehicle injections1,11. Blood glucose
was measured over the duration of the experiment (Figure 1). Rats were given food and
water ad libitum. Body weight and water intake were assessed.
Femur Implant and Inoculation
Fourteen days after becoming diabetic, rats were anesthetized with 2% isoflurane in oxygen.
The right hindlimb skin was shaved, prepped with chlorhexidine and 70% ethanol, and
draped. A 2.5cm incision was made on the lateral aspect of the right thigh parallel to the
femur between the hip and the knee. The plane between the flexor and extensor musculature
was sharply and bluntly dissected. The antero-lateral aspect of the femur was exposed and a
pilot hole was drilled through the proximal cortex of the femoral diaphysis using a 1.5mm
diameter bit. The sterilized fracture plate was screwed onto the femur. The right femur and
implant were inoculated by pipetting 10μl of S. aureus at 2 × 108 CFU/ml onto the fracture
plate. The wound was then closed in two layers suturing the fascia with running 4-0
Maxon™, then suturing the skin with interrupted polypropylene. The procedure was repeated
for the left hindlimb without bacterial inoculation. All rats received a subcutaneous dose of
2.5 mg/Kg flunixin at the time of surgery and then daily for three days.
Explantation
Seven days after implantation, rats were anesthetized and the skin was shaved and prepped
as above. The left hindlimb sutures were removed and a new incision was made directly
over the previous wound. The femur was then exposed using blunt dissection. The vastus
lateralis muscle directly overlying the implant was excised in line with the ends of the plate
roughly approximating the size and shape of the fracture plate. The muscle was then divided
with the proximal segment used to calculate a wet:dry weight and the distal segment for
bacterial quantification. The screw and plate were removed and placed in a sterile container
for biofilm quantification. This procedure was repeated for the right side.
Explant Quantitative Microbiology
The proximal muscle was weighed wet then dried at 50 °C for >24 h. The specimen taken
for culture was weighed wet, minced with dissection scissors, and then homogenized by
adding a volume of sterile PBS buffer equal to ten times the specimen weight (10X dilution
v:w). The homogenate underwent 6 serial 10-fold dilutions and 100μl of each dilution was
plated on TSA plates and incubated for 72 h at 37 °C. After 72 h, the plates containing
between 30–300 colonies were counted for number of CFUs.
Biofilm Assay
Biofilm formation on the explanted hardware was quantified using the technique of
Christensen et al16 and modified by Antoci et al17. Explanted stainless steel implants and
cortical screws were transferred into a sterile Falcon 24-well plate and washed 6 times with
sterile PBS. The hardware was transferred into a glass Vacutainer containing 1ml TSB + 1%
glucose and sonicated for 5 min at 37 °C. Three 300μl aliquots of the sonicated broth were
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transferred into separate wells on the Falcon plate and incubated overnight at 37°C. Broth
was aspirated and each well was washed 3 times with sterile PBS. Crystal Violet (300μl of
1% w:v in PBS) was added and incubated for 5 min at room temperature. The stain was
aspirated and wells were washed three times with sterile PBS. Finally, 300μl of glacial
acetic acid was added to the wells to re-suspend the crystal violet stain. Absorbance was
measured at 595nm using a Genios spectrophotometer running Magellan software (Tecan,
Männedorf, Switzerland).
Study Design
Twenty-four rats were divided into two experimental groups, diabetic (n=16) and non-
diabetic (n=8). All animals received bilateral femur implants and the right hindlimb of each
rat was inoculated with S. aureus, resulting in four rat hindlimb groups. The non-diabetic
(ND) non-inoculated (N) data served to quantify infectious burden without direct inoculation
in non-diabetic rats. The diabetic (DM)-N data were compared to the ND-N data to
determine whether having diabetes alone in the absence of direct inoculation increases
infectious susceptibility. The ND-inoculated (I) data served as a control to see if bacterial
inoculation produces measurable infection in a non-diabetic animal. The DM-I data were
compared to the ND-I group to see if having diabetes has an effect on the immune system’s
ability to fight and clear infection. Additionally, we implanted hardware bilaterally into
control rats without bacterial inoculation. These data were compared to the ND-N data to see
if measurable crossover of bacteria occurs between the inoculated and non-inoculated
hindlimbs.
Statistical Analysis
The median, 25th, and 75th quartile CFU/mg tissue for the diabetic and non-diabetic rats
were calculated using JMP software (SAS, Cary, NC). Since the microbiologic and biofilm
data were not normally distributed, they were compared using a Wilcoxon Rank Sum Test.




Fasting blood glucose measurements for the STZ (diabetic) and vehicle (non-diabetic)
groups were averaged for each day (Figure 1). We observed a significant difference in the
mean blood glucose levels between both groups for all days except day 0 (p < 0.001*).
Average blood glucose for the diabetic group 14 days past initial hyperglycemic
measurement was 466 ± 16 mg/dl (mean ± SEM). The non-diabetic group remained
normoglycemic at 105 ± 11 mg/dl 12 days after receiving the initial vehicle injection (Figure
1).
Body Weight
Body weight was averaged by day and group (Figure 2). We observed a significant
difference in the mean body weight for all days except day 0 (p < 0.001*). Average body
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weight on day 24 was 349 ± 8 g for the non-diabetic group and 205 ± 9 for the diabetic
group (Figure 2).
Quantitative Microbiology
Infectious burden was measured by quantifying CFU of S. aureus 72h after muscle
explantation (Figures 3 & 4). We observed a significantly greater infectious burden
(CFU/mg dry tissue) in the inoculated hindlimb for the diabetic versus non-diabetic group (p
= 0.0003*, Figure 3). The median number of CFU/mg dry tissue in the diabetic group was
approximately six orders of magnitude greater than in the non-diabetic group (Table 1). The
median CFU/mg dry tissue for the non-inoculated limb in the diabetic rats was consistently
above the non-diabetic, however this difference was not significant (Figure 3, Table 1). As
expected, when we compared the bacterial burden for the inoculated vs. non-inoculated
hindlimbs within each group, we detected a significant increase in the CFU/mg dry tissue for
the inoculated limb (Table 1). A significant difference in the CFU/mg dry tissue for the non-
inoculated hindlimb in the diabetic inoculated group when compared to the control (diabetic
non-inoculated) group (p = 0.64, Figure 4) was not observed, indicating lack of bacterial
crossover.
Of the 24 rats in this study, one diabetic rat had to be euthanized prematurely following
unintended femur fracture and one non-diabetic rat died prematurely of unknown etiology.
Additionally, the culture plates of one rat in the diabetic group became contaminated and
those plates were not used for data analysis. Consequently, data from 14 diabetic and 7 non-
diabetic animals were analyzed, respectively.
Biofilm Formation
We observed a significant difference in the normalized absorbance between the diabetic,
1.37 (1.11, 2.06), and non-diabetic groups, 0.92 (0.88, 0.94) (p = 0.0017*; Figure 4). Data
are presented as median (+ 25th, − 75th percentile). Differences in variability in the diabetic
and non-diabetic groups can most likely be attributed to the severity of the disease state in
diabetic animals, in particular variable levels of hyperglycemia, which influences bacterial
adherence and biofilm formation.
4. Discussion
Streptozotocin and Diabetes
Streptozotocin causes selective pancreatic beta cell toxicity via GLUT-2 receptors-
associated uptake18. Single large doses produce diabetes by direct cellular toxicity, whereas
multiple lower doses produce diabetes via secondary autoimmune insulitis, better mimicking
human type-1 diabetes. Importantly, at low doses (40mg/kg) STZ is not broadly cytotoxic
and is not known to directly cause immune dysfunction.
We induced diabetes in 100% of the rats, exceeding results in the literature of 50–90% for
single dose or multiple low-dose regimens22. The rats tolerated the IP injections well with
none exhibiting direct drug toxicity. No rats exceeded 600 mg/dL or required exogenous
insulin.
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With the variety of diabetic models available, choosing an experimental model requires
careful consideration. Generally, drug-induced type-1 diabetes are the most reproducible and
efficient means of generating a stable diabetes23,24. Type-1 diabetes can also be selected for
through inbreeding, i.e. with “non-obese diabetic” (NOD) mice19. However, spontaneous
models are fairly heterogeneous and contain numerous genes related to autoimmune
susceptibility19,20. Type-2 Diabetes is defined by insulin resistance with or without impaired
insulin secretion due to obesity, genetic, and environmental factors19–21. Because of the
complexity of human type-2 Diabetes, no single animal model is currently capable of
representing all aspects of the disease. The specific genotype and phenotype selected for the
disease may differ greatly and confound experimental results. Thus, a type-1 diabetic model
seemed the most suitable for this investigation. The choice of chemical induction with
streptozotocin is due to its efficacy, reproducibility, and controllability19.
Our type-1 diabetic model is a very helpful tool for “diabetic” interrogations. However,
type-2 Diabetes mellitus represents the bigger portion of the diabetic population. Therefore,
the development of a reliable type-2 model needs to be goal of future diabetes research.
Body Weight
Trends in body weight were monitored to ensure no animals experienced wasting secondary
to severe hyperglycemia. The weight gain in the control group was significantly greater in
comparison to the modest gain seen in the diabetic group. We attribute this small gain to the
stresses of the disease state.
Bacterial Quantification
We consistently reproduced our primary endpoint of quantifying S. aureus infections at the
surgical site seven days after plate implantation and bacterial inoculation. Showing a
decreased ability to fight post-operative infections, our data aligns with the abundant
literature on diabetic pathophysiology in rats. Secondary manifestations of diabetes such as
immune dysfunction and impaired wound healing explain the increased infectious burden
seen in our study.
With respect to immune dysfunction, diabetes can best be thought of as a mild
immunocompromised state, with most immunologic defects occurring in the cellular innate
immune system22. Multiple dysfunctions in both neutrophils and macrophages exist (Table
2). Neutrophil dysfunction includes altered activation, increased cell adhesion, altered
chemotaxis, and decreased phagocytosis23. Macrophage dysfunction includes decreased cell
count, immunogenicity, phagocytic rate, and antigen presenting ability24. With respect to
wound healing, our group recently published a review addressing the impaired deep tissue
healing at the site of implantation in diabetic animals25. To date, over 100 known
pathophysiological factors have been discovered that contribute to impaired wound healing
in individuals with diabetes26. These include but are not limited to decreased or impaired
growth factor secretion27–29, angiogenic response29,30, collagen accumulation, quality of
granulation tissue29, and delayed bone healing31–36. Delayed bone healing can lead to mal-
union and subsequently hardware fracture requiring revision surgery. Decreased blood flow
to the site of implantation predisposes infection. Immunologic dysfunction and delayed
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wound healing contribute to the increased postoperative infectious burden of the diabetic
patient. Importantly, the rodent immunologic dysfunction observed here must be cautiously
interpreted since the immune response to infection seen in humans could differ37,38.
Although our surgical model is novel, we are not the first group to look at in vivo infection
susceptibility to S. aureus in diabetic rodents. S. aureus injection in the hind paw of both
type-1 and type-2 diabetic rodents causes a significantly higher mean bacterial burden when
compared to non-diabetics39. Importantly, this study also showed that strict glucose
regulation improved immune function in the diabetic animals. Although the degree of
immune dysfunction seems proportional to blood glucose, further research is necessary to
investigate whether control of blood glucose levels with exogenous insulin affects the
infectious burden in our model.
Biofilm Formation
Biofilm formation is of interest to our study as its presence makes treating orthopedic
implant infections extremely difficult. Due to S. aureus’ ability to generate biofilm on
hardware, we indirectly quantified the degree of biofilm formation on our implants. Our
results showed a significant increase in the ability of S. aureus to form a biofilm on the
implanted hardware in the diabetic animals. It is known that the majority of biofilm
formation occurs during the early post-operative period. Thus, immediately after bacterial
inoculation becomes the critical period when the body must prevent bacterial adherence to
the implanted hardware. However, the early immune response to infection is dominated by
neutrophils, and without an intact innate cellular immune response S. aureus is able to freely
colonize the implant. Importantly, normalizing the absorbance values was required due to
intra-experimental variability in the absolute absorbance values detected by our
spectrophotometer. We believe the relative values obtained are reliable because the
inoculated and non-inoculated sides for a given animal were analyzed simultaneously.
Study Limitations
In our study, we are limited in drawing conclusions about the infectious susceptibility of our
diabetic animals when compared to non-diabetics. Insight into infectious susceptibility
comes from the bacterial quantification data in the non-inoculated hindlimb. One would
assume that the non-inoculated hindlimbs of both groups would have approximately the
same degree of bacterial burden if their infectious susceptibility was the same. However, this
was not the case, as the diabetic group had increased bacterial burden in the non-inoculated
hindlimb when compared to the non-diabetic group. Even in the absence of direct
inoculation, the diabetic group was more susceptible to a more severe post-operative
infection than the non-diabetic group. This trend is consistent with recent reports in the
literature, which point to a variety of factors that contribute to infection susceptibility14,25,
including decreased inflammatory response, poor angiogenic response, and nitric oxide
deficiency. Insufficient power is likely why the two The fact that a significant difference
could not be detected between the two groups is groups could not be distinguished, as the
sample size for our study was small. Additonally, the duration of the study may affect the
bioburden as it is possible the infection for the diabetic animals would worsen over time
while the infection in control subjects may clear. In contrast, the difference between the
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bioburden of the inoculated and non-inoculated non-diabetic rats was statistically
significant. This discrepancy may be attributed to the variability of the infectious burden in
the diabetic non-inoculated group. While some diabetic wounds exhibited considerable
infection in the absence of inoculation, others had none. In contrast, data obtained from non-
diabetic rats was much less variable. The severity of the disease state in the diabetic rats may
thus influence the variability. Rats with more severe hyperglycemia (>500 mg/dl) may
exhibit greater immune deficiency resulting in increased infectious burden in comparison to
rats with moderate hyperglycemia (350–500 mg/dl). Importantly, we attribute the bacterial
growth in the non-inoculated hindlimb of both groups to normal bacterial burden from
surgery, even though every effort was made to remain sterile for the entirety of the
operations.
Our study was limited in its ability to quantify total infectious burden at the surgical site as
we harvested only the muscle directly overlying the fracture plate. Although it is likely that
the infections were not localized, the technique we employed provided the accuracy and
precision needed to detect statistically significant differences via tissue plate quantification
method. Lastly, our model of directly inoculating the surgical site with concentrated bacteria
does not mimic real-life acquisition of a surgical infection.
5. Conclusion
The extensive literature on immune dysfunction and delayed wound healing in diabetic
patients emphasizes the need to study post-operative infections in diabetic animals. The
novel outcomes-based STZ dosing regimen presented here induced diabetes in 100% of the
rats and achieved consistent hyperglycemic values. Diabetic rats demonstrated elevated
infection proclivity above non-diabetics after S. aureus inoculation in the presence of
implanted hardware. These data support the hypothesis that uncontrolled type-1 diabetes
adversely affects the immune system’s ability to fight and clear bacteria in the post-
operative period.
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Average blood glucose (mg/dl) for both the STZ (n=16, q2 days) and Vehicle (n=8, q4 days)
rats. There was a significant increase in the mean blood glucose for the STZ group when
compared to the Vehicle group for all days except day 0 (p< 0.0001*).
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Average body weight (g) for both the diabetic (n=16, q2 days) and non-diabetic (n=8, q4
days) rats. There was a significant difference in the mean body weight between the diabetic
and non-diabetic groups for all days except day 0 (p< 0.0001*).
Brown et al. Page 12























Infectious burden in the inoculated (A) and non-inoculated hindlimb (B) for both the
diabetic (n=14) and non-diabetic (n=7) groups quantified by plate culture method. Box plot
data represent median, 25th, 75th percentiles, with whiskers representing minimum and
maximum values. Vertical axis is logarithmic base 10 scale with values representing power
of the base. There was a significant difference in the concentration of bacteria cultured for
the inoculated hindlimb between the diabetic and non-diabetic groups (p = 0.0003*). There
was not a significant difference detected in the infectious burden for the non-inoculated
hindlimb between the diabetic and non-diabetic groups (p = 0.0682).
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Normalized absorbance of hardware as measured by indirect staining of biofilm adherent to
the fracture plate and screws in both the diabetic and non-diabetic groups. Box plot data
represent median, 25th, 75th percentiles, with whiskers representing ± 1.5 times the
interquartile range. Data represent values for the hardware of the inoculated hindlimb of
each group after normalization to the hardware of non-inoculated hindlimb. Dashed red line
has a value of 1 and represents the non-inoculated hindlimb absorbance data. There was a
significant increase in the amount of biofilm detected in the inoculated hindlimb of the
diabetic rats (p = 0.0017*).
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